Pfenex, BARDA Extends Anthrax Vaccine Pact - - BioPharm International

ADVERTISEMENT

Pfenex, BARDA Extends Anthrax Vaccine Pact



Pfenex, a biotechnology company offering recombinant protein expression, and the Department of Health and Human Services, through the Biomedical Advanced Research and Development Authority (BARDA), have modified its prime contract and exercised an option associated with their existing contractual relationship that began in July 2010. This modified agreement extends the prime contract and increases the funding to support the development of a recombinant protective antigen (rPA)-based anthrax vaccine based on rPA produced in the company’s platform technology, Pfēnex Expression Technology.  The increase in funding of approximately $8.0 million brings the total funding available to approximately $23.9 million over the course of the contract if all options are exercised.

During the contract’s base period, Pfenex demonstrated that a strongly immunogenic, stable, and protective form of rPA could be expressed and recovered from the fermentation of a strain of P. fluorescens engineered to produce rPA. The exercise of this option allows for the completion of preclinical studies, implementation of analytical methods, and cGMP manufacturing.

Source: Pfenex

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Hospira Issues Recall Due to Mold Contamination
July 11, 2014
Baxter Issues Recall Due to Particulate Matter
July 11, 2014
FDA Publishes Guidance on ANDA Submissions
July 10, 2014
Biotech Industry Forms International Council
July 10, 2014
EMA Recommends 39 Drugs in First Half of 2014
July 10, 2014
Author Guidelines

Click here